BR112015022472A2 - método e sistema para prever a resposta a tratamentos para transtornos mentais - Google Patents

método e sistema para prever a resposta a tratamentos para transtornos mentais

Info

Publication number
BR112015022472A2
BR112015022472A2 BR112015022472A BR112015022472A BR112015022472A2 BR 112015022472 A2 BR112015022472 A2 BR 112015022472A2 BR 112015022472 A BR112015022472 A BR 112015022472A BR 112015022472 A BR112015022472 A BR 112015022472A BR 112015022472 A2 BR112015022472 A2 BR 112015022472A2
Authority
BR
Brazil
Prior art keywords
treatments
mental disorders
predicting response
treatment
predicting
Prior art date
Application number
BR112015022472A
Other languages
English (en)
Inventor
Chawla Aditi
Vilalta Adrian
Tomar Alok
Hellman Andrew
Del Tredici Andria
Wang Cindy
K Becker David
ZHU Guangdan
Nova Michael
Kuo-Fu Chan Russell
Ivanova Gramatikova Svetlana
Moreno Tanya
Original Assignee
Pathway Genomics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pathway Genomics Corp filed Critical Pathway Genomics Corp
Publication of BR112015022472A2 publication Critical patent/BR112015022472A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/30—Prediction of properties of chemical compounds, compositions or mixtures
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medical Informatics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Data Mining & Analysis (AREA)
  • Theoretical Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Computing Systems (AREA)
  • Databases & Information Systems (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Epidemiology (AREA)
  • Primary Health Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

“método e sistema para prever a resposta a tratamentos para transtornos mentais” resumo a presente invenção refere-se a métodos e ensaios para prever a resposta de um indivíduo para o tratamento psiquiátrico e a um método para melhorar o tratamento de uma desordem médica, que responde ao tratamento com um tratamento psiquiátrico. 1/1
BR112015022472A 2013-03-15 2014-03-12 método e sistema para prever a resposta a tratamentos para transtornos mentais BR112015022472A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361800206P 2013-03-15 2013-03-15
US201361800278P 2013-03-15 2013-03-15
US13/917,573 US20140274764A1 (en) 2013-03-15 2013-06-13 Method and system to predict response to treatments for mental disorders
PCT/US2014/024314 WO2014150817A2 (en) 2013-03-15 2014-03-12 Method and system to predict response to treatments for mental disorders

Publications (1)

Publication Number Publication Date
BR112015022472A2 true BR112015022472A2 (pt) 2017-07-18

Family

ID=51529822

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015022472A BR112015022472A2 (pt) 2013-03-15 2014-03-12 método e sistema para prever a resposta a tratamentos para transtornos mentais

Country Status (5)

Country Link
US (3) US20140274764A1 (pt)
EP (1) EP2973364A4 (pt)
BR (1) BR112015022472A2 (pt)
HK (1) HK1220279A1 (pt)
WO (1) WO2014150817A2 (pt)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL199534A (en) 2007-01-05 2013-01-31 Univ Zuerich An isolated human antibody capable of detecting a neoepitope in a disease-related protein, a polynucleotide encoding an antibody, a vector containing the polynucleotide, a host cell containing the polynucleotide or vector, a preparation containing the antibody and related methods and uses.
EP3019629A4 (en) * 2013-07-12 2017-01-18 Biogen International Neuroscience GmbH Genetic and image biomarkers associated with decline in cognitive measures and brain glucose metabolism in populations with alzheimer's disease or those susceptible to developing alzheimer's disease
US11037684B2 (en) * 2014-11-14 2021-06-15 International Business Machines Corporation Generating drug repositioning hypotheses based on integrating multiple aspects of drug similarity and disease similarity
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
WO2016123543A1 (en) * 2015-01-30 2016-08-04 Takeda Pharmaceuticals U.S.A., Inc. Method for treating schizophrenia comprising administering lurasidone
US9932638B2 (en) 2015-06-29 2018-04-03 Millennium Health, LLC Single nucleotide polymorphism in HLA-B*15:02 and use thereof
WO2017161289A1 (en) * 2016-03-18 2017-09-21 Takeda Pharmaceutical Company Limited Method for identifying clinical trial responders from a placebo group in major depression
WO2017165423A1 (en) * 2016-03-21 2017-09-28 Indiana University Research & Technology Corporation Drugs, pharmacogenomics and biomarkers for active longevity
CN110087640A (zh) 2016-12-20 2019-08-02 罗曼治疗系统股份公司 包含阿塞那平的透皮治疗系统
KR102614709B1 (ko) 2016-12-20 2023-12-18 에르테에스 로만 테라피-시스테메 아게 아세나핀 및 폴리실록산 또는 폴리이소부틸렌을 함유하는 경피흡수 치료 시스템
US11033512B2 (en) 2017-06-26 2021-06-15 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and silicone acrylic hybrid polymer
AU2018204841B2 (en) * 2017-07-05 2023-08-10 Medtronic Ardian Luxembourg S.A.R.L. Methods for treating post-traumatic stress disorder in patients via renal neuromodulation
IL272773B2 (en) 2017-08-22 2024-06-01 Biogen Ma Inc Pharmaceutical preparations containing anti-amyloid cell antibodies
WO2019046303A1 (en) * 2017-08-28 2019-03-07 The Trustees Of Columbia University In The City Of New York METHOD FOR PREDICTING PATIENT RESPONSE TO SLC MODULATOR PROCESSING
WO2019090421A1 (en) * 2017-11-07 2019-05-16 MedReleaf Corp. Dosage and varietal recommendations for the treatment of medical conditions using cannabis
CN108070659B (zh) * 2017-12-27 2020-05-05 中国医学科学院肿瘤医院 Snp标志物在预测tam辅助内分泌治疗乳腺癌患者疗效中的应用
CN108319807B (zh) * 2018-01-05 2019-12-17 东北大学 一种掺杂式能源材料的高通量计算筛选方法
KR102047479B1 (ko) * 2018-01-24 2019-11-21 전남대학교산학협력단 노년기우울증 검출방법 및 진단키트
CN108179192A (zh) * 2018-02-06 2018-06-19 徐州医科大学 一种基因多态性变异位点早期诊断子宫内膜癌的试剂盒
US20190264285A1 (en) * 2018-02-23 2019-08-29 Northwestern University Polymorphisms for predicting treatment response to antipsychotic drugs and idenfying new drug targets
CN108546754B (zh) * 2018-05-08 2021-12-03 上海交通大学医学院附属上海儿童医学中心 一种基于多色探针熔解曲线分析的喹硫平、阿立哌唑药物基因组学检测方法
KR20210022656A (ko) 2018-06-20 2021-03-03 에르테에스 로만 테라피-시스테메 아게 아세나핀을 함유하는 경피 치료 시스템
CN109112188A (zh) * 2018-06-26 2019-01-01 苏州道尔盾基因科技有限公司 一种hla-b*1502基因的检测方法及检测试剂盒
WO2020092240A1 (en) * 2018-10-29 2020-05-07 Northwestern University Big data-driven personalized management of chronic pain
KR102219694B1 (ko) * 2018-11-22 2021-02-24 인제대학교 산학협력단 항정신용제 약물 반응 및 부작용과 관련된 cyp3a5, ugt2b15, comt, htr2a 및 bndf의 대립유전자에 대한 검출 방법
CN109439742A (zh) * 2018-12-07 2019-03-08 北京华夏时代基因科技发展有限公司 用于质子泵抑制药代谢和耐药基因snp检测的核苷酸组合
WO2020132691A1 (en) * 2018-12-21 2020-06-25 Thsee, Llc Method for optimization of cannabis dosage and mixture of active cannabinoids
US20200211688A1 (en) * 2018-12-28 2020-07-02 Xing-Liang Liu Method and system for providing a personalized cannabinoid treatment regimen
US20200234810A1 (en) * 2019-01-23 2020-07-23 The Regent Of The University Of Michigan Pharmacogenomic Decision Support for Modulators of the NMDA, Glycine, and AMPA Receptors
CN109825574A (zh) * 2019-03-20 2019-05-31 宁波海尔施基因科技有限公司 一种用于抗癫痫药物用药指导的多重基因检测试剂盒及其使用方法
MX2021012383A (es) * 2019-04-09 2022-01-04 Vistagen Therapeutics Inc Variantes genéticas asociadas con la respuesta al tratamiento de trastornos neurológicos.
WO2020216832A1 (en) * 2019-04-24 2020-10-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for predicting the response of antipsychotic drugs
CN110079596A (zh) * 2019-04-26 2019-08-02 宁波海尔施基因科技有限公司 一种用于抗躁狂药物用药指导的多重基因检测试剂盒及其使用方法
RU2717245C1 (ru) * 2019-12-13 2020-03-19 Государственное бюджетное учреждение здравоохранения города Москвы "Московский научно-практический центр наркологии Департамента здравоохранения города Москвы" (ГБУЗ "МНПЦ наркологии ДЗМ") Способ прогнозирования оценки эффективности терапии дапоксетином для лечения расстройств, сопровождающихся развитием депрессивной симптоматики
RU2734347C1 (ru) * 2019-12-13 2020-10-15 Федеральное государственное бюджетное образовательное учреждение дополнительного профессионального образования "Российская медицинская академия непрерывного профессионального образования" Министерства здравоохранения Российской Федерации (ФГБОУ ДПО РМАНПО Минздрава России) Способ прогнозирования оценки эффективности терапии миртазапином для лечения расстройств, сопровождающихся развитием депрессивной симптоматики
US20210398631A1 (en) * 2020-06-18 2021-12-23 Genomind, Inc. Systems and methods for displaying a patient specific report
CN115515680A (zh) * 2020-03-06 2022-12-23 索元生物医药有限公司 用于评估神经递质转运蛋白抑制剂的功效的组合物和方法
JP6893052B1 (ja) * 2020-06-29 2021-06-23 ゲノム・ファーマケア株式会社 投与計画提案システム、方法およびプログラム
CN112174902A (zh) * 2020-09-29 2021-01-05 广州万孚生物技术股份有限公司 一种奥沙西泮半抗原、奥沙西泮抗原及其制备方法和应用
EP4247259A4 (en) * 2020-11-18 2024-10-16 Indiana Univ Research And Technology Corporation METHODS FOR OBJECTIVE ASSESSMENT, RISK PREDICTION, CORRESPONDING TO EXISTING AND NEW DRUGS METHODS FOR USING DRUGS AND MONITORING RESPONSES TO TREATMENTS FOR MOOD DISORDERS
CN113136424B (zh) * 2021-05-21 2022-04-08 广州合一生物科技有限公司 一种用于抗癫痫药物个体化用药的基因检测试剂盒及其应用
CN113373211A (zh) * 2021-05-26 2021-09-10 郑州大学 一种用于指导焦虑症用药的相关基因检测试剂盒及应用
CN113468867B (zh) * 2021-06-04 2024-06-11 淮阴工学院 一种基于Attention机制的参考文献引用合法性预测方法
CN113755581B (zh) * 2021-09-27 2024-08-16 厦门市仙岳医院(厦门市精神卫生中心) 基质辅助激光解吸飞行时间质谱检测精神类疾病用药相关基因的核酸组合物、试剂盒和方法
CN114941030B (zh) * 2022-04-29 2023-05-05 南京医科大学 一种用于胃癌辅助诊断的snp标志物及其应用
WO2024025536A1 (en) * 2022-07-28 2024-02-01 Indiana University Research And Technology Corporation Precision medicine for anxiety disorders: objective assessment, risk prediction, pharmacogenomics, and repurposed drugs
CN116515993A (zh) * 2023-06-25 2023-08-01 广州凯普医药科技有限公司 用于抑郁症用药基因检测的引物组和试剂盒
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020012921A1 (en) * 2000-01-21 2002-01-31 Stanton Vincent P. Identification of genetic components of drug response
ES2575903T3 (es) * 2003-02-20 2016-07-04 Mayo Foundation For Medical Education And Research Métodos para seleccionar medicamentos antidepresivos
WO2008066769A2 (en) * 2006-11-29 2008-06-05 Lohocla Research Corporation Genetic diagnosis of depression
US7795033B2 (en) * 2007-03-19 2010-09-14 The United States Of America As Represented By The Department Of Health And Human Services Methods to predict the outcome of treatment with antidepressant medication
CA2699786C (en) * 2007-09-10 2019-08-13 Vanda Pharmaceuticals, Inc. Antipsychotic treatment based on snp genotype
US8355927B2 (en) * 2010-11-05 2013-01-15 Genomind, Llc Neuropsychiatric test reports
US20140243608A1 (en) * 2011-07-05 2014-08-28 Robert D. Hunt Systems and methods for clinical evaluation of psychiatric disorders

Also Published As

Publication number Publication date
US20150292014A1 (en) 2015-10-15
WO2014150817A2 (en) 2014-09-25
WO2014150817A3 (en) 2014-11-13
EP2973364A4 (en) 2016-09-28
US20140274764A1 (en) 2014-09-18
EP2973364A2 (en) 2016-01-20
US20170051350A1 (en) 2017-02-23
HK1220279A1 (zh) 2017-04-28

Similar Documents

Publication Publication Date Title
BR112015022472A2 (pt) método e sistema para prever a resposta a tratamentos para transtornos mentais
EA201692477A1 (ru) Композиции и способы применения для лечения метаболических расстройств
BR112017007767A2 (pt) canabidiol para uso, método para tratar um paciente que sofre de complexo esclerose tuberosa, e, composição.
BR112015028605A2 (pt) método para prevenir, inibir ou tratar um ou mais sintomas associados com uma doença do sistema nervoso central
BR112016005816A2 (pt) Combinação de anticorpos anti-lag-3 e anticorpos anti-pd-1 para tratar tumores
CR20140591A (es) Métodos para reducir el riesgo de un evento cardiovascular en tratamientos con estatinas
BR112015019995A2 (pt) Combinação terapêutica envolvendo anticorpos contra claudina 18.2 para tratamento de câncer
MX2016014306A (es) Marcadores para terapia con lipoproteinas de alta densidad (hdl).
BR112015009746A2 (pt) Agente que aumenta atividade de glicocerebrosidase em mamíferos
PH12015500114B1 (en) HUMAN ANTIBODIES TO GFRa3 AND METHODS OF USE THEREOF
BR112012020101A2 (pt) método diagnósticos e terapêuticos usando anticorpos anti-cd200.
EA201591417A1 (ru) Новый способ диагностики депрессии и мониторинга эффективности терапии
BR112015018360A2 (pt) terapia de combinação para o tratamento de pneumonia nosocomial
BR112015004465A2 (pt) sistemas, dispositivos e métodos para fornecer terapia com orientação de imagem
BR112016012840A2 (pt) Derivado de pirimidina e fonte de ácido graxo para uso no tratamento de prisão de ventre
BR112015017241A2 (pt) doadores de nitroxil com índice terapêutico melhorado
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
GT201400223A (es) Sistemas y métodos para tratar una respuesta farmacodinámica adversa inducida por opioides
BR112017000978A2 (pt) mioinositol e probióticos e usos
BR112015022473A2 (pt) método e sistema para prever a resposta a tratamentos contra a dor
MX2016003002A (es) Metodos para determinar la respuesta a la terapia.
EA201592265A1 (ru) Маркер для ассоциированных с кислой сфингомиелиназой нарушений и его применения
BR112015018019A2 (pt) codificadores de áudio, decodificadores de áudio, sistemas, métodos e programas de computador utilizando uma resolução temporal elevada na proximidade temporal de iniciações ou compensações de fricativos ou africativos
BR112016012248A2 (pt) método de tratamento de nefropatia
EP3125756A4 (en) System and method of identifying sources associated with biological rhythm disorders

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired